IMCR

Immunocore Holdings plc IMCR

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,269 of 2,925

Why it scores 36Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$115.93M

Quarter to Jun 30

Net income

$-808.0K

Quarter to Jun 30

Free cash flow

$15.14M

Quarter to Jun 30

Operating margin

-2.6%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.95B total
WELLINGTON MANAGEMENT GROUP LLP
$202.26M-4.9%
RTW INVESTMENTS, LP
$154.62M0.0%
FMR LLC
$136.76M-10.8%
PRIMECAP MANAGEMENT CO/CA/
$115.51M-1.5%
Bellevue Group AG
$88.53M-0.3%
TANG CAPITAL MANAGEMENT LLC
$84.12M0.0%
LINDEN ADVISORS LP
$71.94M-13.8%
Vestal Point Capital, LP
$57.15M-34.9%
TWO SIGMA INVESTMENTS, LP
$52.36M+61.5%
MILLENNIUM MANAGEMENT LLC
$50.71M+29.1%
ARMISTICE CAPITAL, LLC
$45.34M+20.2%
Caligan Partners LP
$43.86MNew
Kynam Capital Management, LP
$43.66M+55.4%
PRICE T ROWE ASSOCIATES INC /MD/
$41.16M-7.2%
BVF INC/IL
$41.10M0.0%
CAMDEN ASSET MANAGEMENT L P /CA
$40.68M+4.1%
BlackRock, Inc.
$39.35M+30.7%
ACADIAN ASSET MANAGEMENT LLC
$38.39M+141.5%
Trails Edge Capital Partners, LP
$33.76M+55.8%
Point72 Asset Management, L.P.
$31.44M-10.2%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$27.10M0.0%
Jupiter Topco LLC
$22.50M--
Logos Global Management LP
$19.05M-60.0%
MARSHALL WACE, LLP
$18.76M+227.7%
Hudson Bay Capital Management LP
$18.73M-6.8%
See all 155 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IMCR

Earnings Per Share

13fpro.ai/company/IMCR

Loading ratio trend…

IMCR key financials by period

Reported revenue, net income and operating margin by fiscal year, from Immunocore Holdings plc's annual filings on SEC EDGAR.

Immunocore Holdings plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$400.0M$-35.5M-11.3%
FY 2024$310.2M$-51.1M-22.7%
FY 2023$249.4M$-55.3M-23.9%
FY 2022$174.4M$-52.5M-29.7%
FY 2021$36.5M$-180.0M—
Source: IMCR filings on SEC EDGAR →

Companies similar to IMCR

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

IMCR insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Immunocore Holdings plc (IMCR): stock profile, AI score and financials

Immunocore Holdings plc (IMCR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMCR at 36.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,269 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Immunocore Holdings plc reports quarterly revenue of $115.9M, net income of $-808.0K, an operating margin of -2.6%. Top institutional holders of IMCR by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, RTW INVESTMENTS, FMR, based on the most recent SEC filings. IMCR trades on the Nasdaq exchange and files with the SEC under CIK 1671927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunocore Holdings plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1671927 →